يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
UPDATE 2-Bristol-Myers Squibb to acquire Mirati in $4.8 billion deal
داو جونز الصناعي -0.09%
إس آند بي 500 -0.16%
ناسداك -0.59%
Mirati Therapeutics Inc. 0.00%
بريستول مايرز سكويب كو +3.59%
Dow Jones Industrial Average DJI | 48416.56 | -0.09% |
S&P 500 index SPX | 6816.51 | -0.16% |
NASDAQ IXIC | 23057.41 | -0.59% |
Mirati Therapeutics Inc. MRTX | 58.70 | 0.00% |
Bristol-Myers Squibb Company BMY | 54.29 | +3.59% |
Adds details from statement in paragraphs 4,5, background in paragraph 6
Oct 8 (Reuters) - Bristol-Myers Squibb BMY.N on Sunday said it will acquire cancer drugmaker Mirati Therapeutics MRTX.O for $58 per share in cash, representing $4.8 billion equity value.
Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.
The transaction is expected to be dilutive to Bristol-Myers Squibb's non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.
Mirati stockholders will receive one non-tradeable Contingent Value Right for each Mirati share held, potentially worth $12.00 per share in cash.
The U.S. health regulator had in December approved Mirati's lung cancer drug, Krazati, to treat adults with advanced lung cancer.
(Reporting by Dimpal Gulwani; Additional reporting by Lavanya Ahire; Editing by Lisa Shumaker and Diane Craft)
((Dimpal.Gulwani@thomsonreuters.com;))
